Acuta Capital Partners’s Cidara Therapeutics CDTX Stock Holding History

Acuta Capital Partners’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-89,145	Closed	-$19.7M	–	28
2025 Q4	$19.7M	Sell	89,145 -52,384	-37%	-$8.47M	13.37%	3
2025 Q3	$13.6M	Sell	141,529 -38,040	-21%	-$2.43M	14.01%	2
2025 Q2	$8.75M	Buy	179,569 +53,861	+43%	+$1.29M	12.21%	2
2025 Q1	$2.71M	Buy	125,708 +71,235	+131%	+$1.58M	3.14%	11
2024 Q4	$1.46M	Buy	+54,473	New	+$885K	1.47%	24
2015 Q4	–	Sell	-2,956	Closed	-$752K	–	60
2015 Q3	$752K	Sell	2,956 -3,544	-55%	-$1.01M	0.44%	49
2015 Q2	$1.82M	Buy	+6,500	New	+$2M	1.13%	28

Acuta Capital Partners's CDTX Position: Q1 2026 in Review

Acuta Capital Partners sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 89,145 shares — an estimated $19.7M sold.

Acuta Capital Partners first reported a position in CDTX in Q2 2015 and held it in 7 quarters. The position peaked at $19.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Acuta Capital Partners reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Acuta Capital Partners sold 89,145 Cidara Therapeutics shares in Q1 2026, an estimated $19.7M.
Acuta Capital Partners first reported a position in Cidara Therapeutics in Q2 2015 and held it in 7 quarters.
Acuta Capital Partners's Cidara Therapeutics position peaked at $19.7M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.